



News Release

Suven Revenue up by 9%; PAT up by 23% for the year ended March 2017

HYDERABAD, INDIA (13 May' 2017) – SUVEN LIFE Sciences Limited, a biopharmaceutical company specialized in CRAMS for global life science companies and drug discovery and developmental activities in Central Nervous System disorders, today announced its audited financial results for the quarter ended 31st March 2017. The audited financial results were reviewed by the audit committee and approved by the Board of Directors in their meeting held on 13th May' 2017 at Hyderabad.

Financial Highlights for the 4th Quarter ended March' 2017 (QoQ):

Growth in income	INR 1850 Mn vs 1204 Mn - up by 54%
Growth in PAT	INR 401 Mn vs 243 Mn - up by 65%
Growth in EBIDTA	INR 531 Mn vs 417 Mn – up by 27%

Financial Highlights for the year ended March' 2017:

Growth in income	INR 5656 Mn vs 5196 Mn - up by 9%
Growth in PAT	INR 1235 Mn vs. 1001 Mn - up by 23%
Growth in EBIDTA	INR 1864 Mn vs 1492 Mn - up by 25%

Suven's expenses on innovative R&D in Drug Discovery stood at INR 649 Mn (11.48% on revenue) for the year ended Mar' 2017.

On consolidation of the accounts of Suven, Inc., USA, the wholly owned subsidiary, the PAT reduced to INR 872 Mn and expenditure on R&D increased to INR 991 Mn.

For more information on Suven please visit our Web site at <http://www.suven.com>

Risk Statement:

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive;